Pfizer have developed the Masterclass series to provide an opportunity to increase disease awareness and diagnostic skills amongst less experienced european physicians – those that may have no or little awareness of TTR-FAP. The series is provided as part of Pfizer’s ongoing commitment to improve patient care in this field. The course should equip clinicians with the latest information on recognising and diagnosing TTR-FAP patients to facilitate best practice. In particular, the agenda should feature practical sessions. This will be a 1.5-day meetings with approximately 20 attendees held at Heidelberg
Objectieves: The focus of the Masterclass is patient identification
•Increase awareness of the ‘red flag’ symptoms of TTR-FAP and raise physiciansuspicion of this disease
•Up-skill physicians on the practical identification of TTR-FAP in at-risk patients and shorten the time to initial diagnosis of ‘index’ patients
•Support identification of at-risk family members
Pfizer ontwikkelt innovatieve geneesmiddelen die bijdragen aan de gezondheid en kwaliteit van leven.
Vanuit haar visie en missie ziet Pfizer het toenemend als haar taak om te faciliteren op het gebied van deskundigheidsbevordering en nascholing. Dit gebeurd onder de vlag van 'Pfizer Educatie'. De door Pfizer Educatie ontwikkelde nascholingen richten zich niet alleen op indicatiegebieden, maar bestrijken vooral ook het brede terrein van praktijkondersteuning in algemene zin.